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As it has been established that demethylation of lysine 27 of histone H3 by the lysine-speciﬁc deme-
thylase JMJD3 increases immune responses and thus elicits inﬂammation, we hypothesize that inhibition
of JMJD3 may attenuate autoimmune disorders.
We found that in vivo administration of GSK-J4, a selective inhibitor of JMJD3 and UTX, ameliorates the
severity of experimental autoimmune encephalomyelitis (EAE). In vitro experiments revealed that the
anti-inﬂammatory effect of GSK-J4 was exerted through an effect on dendritic cells (DCs), promoting a
tolerogenic proﬁle characterized by reduced expression of costimulatory molecules CD80/CD86, an
increased expression of tolerogenic molecules CD103 and TGF-b1, and reduced secretion of proin-
ﬂammatory cytokines IL-6, IFN-g, and TNF. Adoptive transfer of GSK-J4-treated DCs into EAE mice
reduced the clinical manifestation of the disease and decreased the extent of inﬂammatory CD4þ T cells
inﬁltrating the central nervous system. Notably, Treg generation, stability, and suppressive activity were
all exacerbated by GSK-J4-treated DCs without affecting Th1 and Th17 cell production. Our data show
that GSK-J4-mediated modulation of inﬂammation is achieved by a direct effect on DCs and that systemic
treatment with GSK-J4 or adoptive transfer of GSK-J4-treated DCs ex vivo may be promising approaches
for the treatment of inﬂammatory and autoimmune disorders.
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
There is considerable evidence suggesting that epigenetic
mechanisms may mediate the development of inﬂammation by
modulating the expression of proinﬂammatory cytokines and the
activation of the transcription factor NF-kb [1e4]. Changes in the
epigenetic modiﬁcation pattern on gene promoters, such as DNA
methylation and histone acetylation and methylation, have been
involved in the development of some chronic diseases, such as
autoimmune and neurodegenerative disorders and cancer [5e9].
JMJD3, a Jumonji C (JmjC) family of histone demethylases, is
induced by NF-kb in response to inﬂammatory stimuli [10]. JMJD3
and its paralog UTX (ubiquitously transcribed X chromosome, Av. Za~nartu 1482, Santiago,
Rosemblatt).
Ltd. This is an open access article utetratricopeptide repeat protein), speciﬁcally demethylate trime-
thylated lysine 27 in histone H3 (H3K27me3) [11,12], a chromatin
modiﬁcation associated with transcriptional repression [11]. Thus,
NF-kB-induced JMJD3 upregulation links inﬂammation to the
control of H3K27me3, a histone modiﬁcation involved in lineage
determination, differentiation and tissue homeostasis [10e12].
Currently, there is great interest in the development of small
molecules that are inhibitors of the machinery involved in the
generation or removal of post-translational modiﬁcations on his-
tones as therapeutic compounds. In 2013, the ﬁrst selective and
potent inhibitor of JMJD3/UTX demethyltransferase activity, GSK-
J4, was synthesized by GlaxoSmithKline. Subsequently, two
studies have addressed the effect of this drug in immune cells. The
ﬁrst one reported that GSK-J4 attenuates lipopolysaccharide (LPS)-
induced proinﬂammatory cytokine production in primary human
macrophages in vitro [13]. The second one addressed the effects of
this drug in T-cell differentiation in vitro and that Jmjd3-deﬁcientnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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encephalomyelitis (EAE) [14]. However, the efﬁcacy of GSK-J4 in
inﬂammation in vivo in the context of autoimmunity has not yet
been addressed. Thus, this information persuaded us to study the
effect of GSK-J4 in a CD4þ T-cell mediated response in vivo and its
relevance in autoimmunity using a murine model of multiple
sclerosis (MS).
MS is an autoimmune disorder characterized by the progressive
loss of neurological function due to the destruction of the axonal
myelin sheath in several areas of the brain and spinal cord, which is
mediated mainly by autoreactive CD4þ T cells [15]. Some of the
clinical symptoms of the loss of myelin are paralysis, muscle
spasms, optic neuritis, and neuropathic pain [16]. The pathological
features of MS lesions are blood-brain-barrier permeability, myelin
sheath destruction, axonal damage, glial scar formation, and the
presence of inﬂammatory cells inﬁltrated into the central nervous
system (CNS), consisting mostly of lymphocytes [17,18]. Autor-
eactive CD4þ Tcells displaying inﬂammatory phenotypes, such as T
helper 1 (Th1) cells and Th17 cells, are considered important for MS
immunopathogenesis [19e22]. In contrast, regulatory T cells
(Tregs) reduce the activity of inﬂammatory T cells [23e26]. Thus,
the balance between Treg and Th1/Th17 cells determines the clin-
ical manifestation of MS. The most widely used animal model for
human MS is experimental autoimmune encephalomyelitis (EAE),
which induces autoimmunity in mice by immunization with
myelin-derived autoantigens [27]. Immunization involves the
priming and expansion of peripheral CD4þ T cells bearing inﬂam-
matory phenotypes and their subsequent inﬁltration into the CNS
[28]. Importantly, there is evidence indicating that Th1 (IFN-g
producers and expressing T-bet) and Th17 (IL-17 producers and
expressing RORgt) are not the only inﬂammatory CD4þ T cells fa-
voring EAE manifestation [29]. It has been determined that CNS-
inﬁltrating CD4þ T cells expressing transcription factors RORgt
and T-bet correspond to GM-CSF producers, the most pathogenic
CD4þ T-cells in EAE [30,31]. However, it is clear that T cells are not
the only immune cell type involved in MS and EAE pathogenesis, as
an increased number of dendritic cells (DCs) has been found in the
cerebrospinal ﬂuid of patients with MS, where they display an
exacerbated state of maturation [32]. It is thought that in healthy
individuals, DCs resident in the CNS play a role in the induction of
peripheral tolerance to CNS-derived self-constituents, including
myelin. However, due to the abnormal mature phenotype of DCs
and their proximity to inﬁltrated T cells in the CNS of MS patients, it
is thought that these DCs play a key role in presenting self-antigens
and thus re-stimulating autoreactive T cells inﬁltrated into the CNS.
Importantly, DCs obtained from MS patients are prone to promote
Th17 differentiation from naïve CD4þ T cells [33].
In this study, we investigated the therapeutic potential of GSK-J4
on EAE and explored the immunological mechanisms underlying
the effect of the drug. Our results show that systemic treatment
with GSK-J4 or adoptive transfer of GSK-J4-treated DCs attenuated
the inﬂammatory response mediated by CD4þ T cells and the
manifestation of EAE. Thus, our ﬁndings represent new potential
therapeutic approaches for autoimmunity. Also, these data present
the ﬁrst evidence about the role of histone demethylases in the
development of DCs towards a tolerogenic phenotype.
2. Materials and methods
2.1. Animals
Six-to twelve-week-old mice of the C57BL/6 background were
used for all experiments. Wild-type (WT) C57BL/6 and Foxp3-GFP
mice were purchased from The Jackson Laboratory (Bar Harbor,
ME). All mice were maintained and manipulated according toinstitutional guidelines at the pathogen-free facility of Fundacion
Ciencia & Vida after approval by the Ethical Review Committee.
2.2. Antibodies
Anti-CD3 3, anti-CD28, anti-CD16/32, APC-H7 anti-CD4, APC
anti-CD25, PE anti-IL-17A, PECy7 anti-IFNg and PECy7 anti-CD45.1
were purchased from eBioscience (CA, USA). Anti-IL4, anti-IFNg, PE
anti-I-A[b], FITC anti-CD40, PE anti-CD86, FITC anti-CD80, UV421
anti-LAP(TGF-b1), APC anti-CD103, PECy7 anti-PDL-1 and UV421
anti-TCRgd were all purchased from BioLegend (CA, USA). Anti-
H3K4me3 and anti-H3 antibodies were purchased from Abcam
(Cambridge, UK). Anti-H3K27me3 and normal rabbit IgG antibodies
were purchased from Millipore (MA, USA).
2.3. Flow cytometry
The expression of cell surface and intracellular markers on T
cells and DCs was determined by FACS analysis after surface
staining or intracellular staining with speciﬁc anti-mouse anti-
bodies. For cytokine analysis on T cells, cells were stimulated for
4 h at 37 C with 50 ng/mL PMA and 1 mg/mL ionomycin in the
presence of 0.01 mg/mL of brefeldin A (BFA) (Sigma-Aldrich). After
staining for surface markers, cells were ﬁxed with 1% v/v formal-
dehyde and permeabilized with 3% w/v BSA and 0.5% w/v Saponin
and further stained for intracellular proteins. All data were
collected on a FACSCantoII (BD Biosciences) and analyzedwith FACS
Diva software (BD, New Jersey) or FlowJo software (TreeStar).
2.4. Cell isolation and in vitro T-cell differentiation
Naïve CD4þ T cells were obtained from spleens of Foxp3-GFP
mice. Splenic CD4þ T cells from Foxp3-GFP mice were enriched
by negative selection using the CD4 isolation kit II (Miltenyi Biotec)
following the manufacturer's instructions and further puriﬁed by
sorting for CD4þCD25-Foxp3- cells using a FACS ARIA II cell sorter
(Becton Dickinson, NJ, USA). Dendritic cells from spleens of WT
(C57BL/6) mice were enriched by MACS puriﬁcation using the
CD11c microbeads (Miltenyi Biotec). For polarizing experiments,
naïve T cells were stimulated with DCs or with plate-bound anti-
CD3 and soluble anti-CD28 in the presence or absence 10 or 25 nM
GSK-J4 (Tocris Bioscience). For DCs-free stimulations, round-
bottom plates were coated with 10 mg/mL of anti-CD3 diluted in
PBS and 1 mg/mL soluble anti-CD28 was added to the cultures. For
stimulation with DCs, naïve T cells were cultured with DCs at a 5:1
ratio and in the presence of 1 mg/mL anti-CD3 for 4 days. Polarizing
conditions were as follows: for iTreg, 5 ng/mL TGF-b, 100 U/mL IL-2,
10 nM retinoic acid,10 mg/mL anti-IL-4 and 10 mg/mL anti-IFN-g; for
Th17, 5 ng/mL TGF-b, 20 ng/mL IL-6, 10 ng/mL IL-1b, 10 mg/mL anti-
IL-4 and 10 mg/mL anti-IFN-g; for Th1, 100 U/mL IL-2 and 100 U/mL
IL-12.
2.5. Analysis of cytokine mRNA production by real-time RT-PCR
Cells were lysed and RNA was extracted using the TRIzol re-
agent. cDNA (1 mg) was synthesized using oligonucleotide and M-
MLV reverse transcriptase (Promega) according to the manufac-
turer's instructions. A 20-ml real-time PCR reaction included 1 ml
cDNA, 10 ml Brilliant SYBR GreenQRT-PCR Master Mix (Stratagene),
and primers and water as indicated by the manufacturer's in-
structions. PCR was carried out for 40 cycles with 95 C melting
(30 s), 60 C annealing (45 s), and 72 C extension (40 s). All re-
actions were performed on a Stratagene Mx3000P. Primer se-
quences were as follows:
IFNg forward: 50-CGGCACAGTCATTGAAAGCCTA-30,
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IL17 forward 50-TTCATCTGTGTCTCTGATGCT-30,
IL17 reverse 50-AACGGTTGAGGTAGTCTGAG-30,
T-bet forward 50-CCTGTTGTGGTCCAAGTTCAAC-30,
T-bet reverse 50-CACAAACATCCTGTAATGGCTTGT-30,
RORgT forward 50-CAGAGGAAGTCAATGTGGGA-30,
RORgT reverse 50-GTGGTTGTTGGCATTGTAGG-30,
GADPH forward, 50-TCCGTGTTCCTACCCCCAATG-30 and
GADPH reverse, 50-GAGTGGGAGTTGCTGTTGAAG-30,
For relative quantiﬁcation, mRNA expression in each samplewas
normalized by comparison with the GAPDH mRNA expression us-
ing the ddCT method as previously described [34].
2.6. In vitro Treg conversion assays
CD4þFoxp3þ iTreg cells generated in the presence or absence of
10 nMGSK-J4 were puriﬁed by cell sorting, stimulatedwith 1 mg/mL
of anti-CD3ε and co-cultured with dendritic cells at ratio 5:1, under
polarizing conditions towards Th17 (5 ng/mL TGF-b, 20 ng/mL IL-6
and 10 mg/mL anti-IFN-g) or Th1 (100 U/mL IL-2 and 100 U/mL IL-
12).
2.7. In vitro suppression assay
Effector T cells (CD4þCD25-) were labeled with 5 mM of Cell-
Trace Violet (Invitrogen, Carlsbad CA) following the manufacturer's
instructions and stimulated with 1 mg/mL of antibody against CD3ε
(eBioscience) in the presence of CD11cþ splenic DCs at a ratio of
1:2. Labeled Teff cells and CD11cþ were co-cultured for 3d with
puriﬁed CD4þFoxp3þ iTreg cells generated with or without 10 nM
GSK-J4 at ratio 1:0.5; 1:1; 1:2 (Teff:Treg). After 72 h, suppression of
proliferation was determined by ﬂow cytometry analysis of Cell-
Trace Violet dilution in a CD45.1þ gate using a FACS Canto II cy-
tometer (BD) and data were analyzed using FACS Diva software
(BD).
2.8. Pretreatment of DCs and in vitro T-cell differentiation
CD11cþ splenic DCs from C57BL/6 were either left unstimulated
or stimulated with 100 ng/mL LPS (Sigma Chemical Co., St. Louis,
MO) for 16 h in the presence or absence of 10 nM or 25 nM GSK-J4.
After 16 h, these cells were washed, resuspended in fresh media,
and co-cultured with naive CD4þ T cells at ratio of 1:5 in the
presence of 1 mg/mL of an antibody against CD3ε, under polarizing
conditions towards iTreg, Th17 or Th1 as speciﬁed above.
2.9. Dendritic cell phenotyping
CD11cþ splenic DCs from C57BL/6 mice were either left unsti-
mulated or stimulated with 100 ng/mL LPS for 16 h in the presence
or absence of 10 nM or 25 nM GSK-J4. After 16 h, the cells were
incubated for 30 min at 4 C with different combinations of the
following antibodies: anti-I-A[b], anti-CD40, anti-CD86, anti-CD80,
anti-LAP (TGF-b1), anti-CD103 and anti-PDL-1. Fc block (BD Bio-
sciences Pharmingen) was used to block nonspeciﬁc binding to Fc
receptors. These markers were analyzed by ﬂow cytometry using a
FACS Canto II cytometer (BD) and data were analyzed using FACS
Diva software (BD).
2.10. Cytometric bead array
For cytokine secretion, culture supernatants were collected from
CD11cþ splenic DCs fromWT mice cultivated for 16 h as indicated.
Cytokine production was analyzed using the Mouse Th1/Th2/Th17
Cytokine Kit following the manufacturer's instructions (BDBiosciences).
2.11. Western blot
CD11cþ DCs were washed twice with cold phosphate-buffered
saline (PBS) and then lysed in RIPA buffer (50 mM Tris, 150 mM
NaCl, 0.1% SDS, 0.5% Na deoxycholate, 1% NP40) supplemented with
a protease inhibitor cocktail (Sigma-Aldrich, USA). Protein con-
centration of lysates was determined using the Bradford assay
(Pierce, Rockford, IL, USA). Equal protein amounts of cell lysates
were loaded onto SDS gels and subjected to SDS-PAGE. The sepa-
rated proteins were transferred onto PVDF membranes and then
analyzed by Western blotting using anti-H3K27me3, anti-
H3K4me3, anti-H3, anti-JMJD3, anti-EZh2 and anti-b-actin
antibodies.
2.12. Chromatin immunoprecipitation and real time PCR
After cell sorting, CD11cþ DCs were ﬁxed with 1% formaldehyde
for 10 min. The reaction was quenched with 0.125 M glycine for
5 min, and cells were washed twice with PBS, resuspended in cell
lysis buffer (10 mM Tris-HCl pH 8.0, 10 mM NaCl, 0.2% v/v NP-40,
and a protease inhibitor cocktail) for 10 min, and then resus-
pended in nuclear lysis buffer (50 mM Tris-HCl pH 8.0, 10 mM
EDTA, 1% w/v SDS, and a protease inhibitor cocktail). Lysates were
diluted twice in sonication buffer (50 mM HEPES pH 7.9, 140 mM
NaCl, 1 mM EDTA, 1% v/v Triton X-100, 0.1% w/v deoxycholic acid,
0.1% w/v SDS, and a protease inhibitor cocktail) and then sonicated
six times for 5 min on ice to high power with a Bioruptor Plus.
Samples were precleared with rabbit IgG and protein A agarose
(Millipore). Precleared samples (3 mg) were taken as input control
and for ChIP reactions, which were performed overnight at 4 C
with 1 mg of anti-H3K27me3,1 mg of anti-H3K4me3 or 1 mg of rabbit
IgG. Immunocomplexes were isolated with protein A agarose and
washed twice with sonication buffer, once with wash buffer
(500 mM LiCl, 100 mM Tris-HCl pH 8.0, 1% v/v NP-40, and 0.1% w/v
deoxycholic acid), and once with TE (50 mM Tris-HCl pH 8.0 and
2 mM EDTA). Samples were then eluted with 100 ml of the immu-
noprecipitation elution buffer (50 mM NaHCO3 and 1% w/v SDS),
and the cross-link was reversed after incubating the samples at
65 C O/N with 10 mg RNAse and 200 mM NaCl. Finally, the samples
were treated with 1 mg/mL proteinase K and the DNA isolated by
DNA Clean and Concentrator kit (Zymo Research). For quantiﬁca-
tion of the immunoprecipitated DNA, KAPA SYBR FAST (KAPA Bio-
systems) was used according to the manufacturer's instructions.
Immunoprecipitated DNA was quantiﬁed by creating a line of best
ﬁt from a standard curve using serial dilutions of genomic template
DNA to allow normalization of primer sets. Primers for the IL-6 and
TGF-b1 promoters were as follows:
IL-6 forward, 50-CCCACCCTCCAACAAAGATT-30,
IL-6 reverse, 50-GCTCCAGAGCAGAATGAGCTA-30,
TGF-b1 forward, 50-GGCTTTAGTAGTGCTCCGCC-30 and
TGF-b1 reverse, 50-GGGGGCACTGTCTTCATCT-30.
PCR was carried out for 40 cycles with 95 C for 10 s (melting),
59 C for 5 s (annealing) and 72 C for 5 s (extension).
2.13. Generation of DCs
Bone marrow-derived DC precursors from WT mice were pre-
pared as previously described [35]. Brieﬂy, DC precursors were
grown in RPMI 1640 medium (Hyclone, Logan, UT) supplemented
with 5% heat-inactivated FBS (Biological Industries, Beit Haemek,
Israel) and 10 ng/mL recombinant mouse GM-CSF (PeproTech,
Rocky Hill, NJ). On day 5, differentiation of DCs was routinely
assessed obtaining 90% CD11cþ cells. In some experiments, day 5
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Fig. 1. GSK-J4 treatment reduces EAE severity. EAE was induced in C57BL/6 mice by
immunization with pMOG in CFA followed by pertussis toxin injection (see Materials
and Methods). GSK-J4 (0.5 mg/kg of mouse) was administered daily during day 1e5
postinduction. (A) Squeme illustrating the experimental design for treatment of mice
with GSK-J4 after the induction of EAE. (B) Clinical score of mice undergoing EAE
treated with GSK-J4 (black) and vehicle (white). (C) Summary of incidence, onset and
maximum severity on EAE experiment. Data from eight mice in each group, corre-
sponding to a representative from two independent experiments, are shown. Values
represent mean ± SEM. **p < 0.01 as determinated by ManneWhitney U test.
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10 nM GSK-J4 (GSK-J4-treated DCs) for 18 h and used for further
experiments.
2.14. EAE induction and evaluation
Six-to eight-week-old female C57BL/6 WT mice were injected
by subcutaneous injection (s.c.) with 50 mg myelin oligodendrocyte
glycoprotein 35e55 peptide (pMOG; Genetel Laboratories, Madi-
son, WI) emulsiﬁed in Complete Freund's Adjuvant (CFA) (Invi-
trogen) supplemented with heat-inactivated Mycobacterium
tuberculosis H37 RA (Difco Laboratories, Detroit, MI). In addition,
mice received intraperitoneal injection (i.p.) of 500 ng of pertussis
toxin (Calbiochem, La Jolla, CA) on days 0 and 2. Clinical signs were
assessed daily according to the following scoring criteria: 0, no
detectable signs; 1, ﬂaccid tail; 2, hind limb weakness or abnormal
gait; 3, complete hind limb paralysis; 4, paralysis of fore and hind
limbs; and 5, moribund or death. A stock solution of GSK-J4 of
42mg/mL (100mM) was prepared in dimethyl sulfoxide (DMSO) to
preserve stability. Before injection, the stock solutionwas diluted 1/
10 with ethanol (DMSO: ethanol, 1:10 v/v) and brought to a ﬁnal
concentration of 140 mg/mL in PBS. In systemic drug evaluation
experiments, each mouse received daily i.p. injections (from days
0e5) of 100 mL of this solution containing 14.0 mg of the GSK-J4
(equivalent to 0.56 mg/kg of the drug). Control mice received
100 mL of the vehicle during the same period. In other EAE exper-
iments, 106 bone marrow-derived DCs from WT mice were treated
with GSK-J4 or vehicle alone for 16 h, pulsed with 5 mg/mL of pMOG
for 4 h and then transferred i.v. into WT C57BL/6 recipient mice 14
and 7 days before EAE induction [34]. In other adoptive transfer EAE
experiments, CD4þFoxp3þ Treg cells generated in the presence or
absence of 25 nM GSK-J4 were puriﬁed by cell sorting and then
0.75  106 transferred i.v. into WT C57BL/6 recipient mice 1 day
before EAE induction.
2.15. Preparation of CNS mononuclear cells
Mice were perfused through the left cardiac ventricle with cold
PBS. The brain and spinal cord were dissected, and CNS tissue was
cut into small pieces and digested with collagenase D (2.5 mg/mL;
Roche Diagnostics) and DNaseI (1 mg/mL; Sigma) at 37 C for
45 min. Digested tissue was passed through a 70-mm cell strainer
obtaining a single cell suspension that was subjected to centrifu-
gation in a Percoll gradient (70%/30% v/v). Mononuclear cells were
removed from the interphase and resuspended in culture medium
for further analysis.
2.16. Statistical analysis
Data are presented as mean ± SEM and P values were analyzed
using the Student's t-test or one-way ANOVA followed by Dunnett's
test using Prism (GraphPad software). In some cases, P values were
analyzed from ManneWhitney rank sums two-tailed U test by
using GraphPad Prism software. ns, no signiﬁcant; statistically
signiﬁcant values are expressed as *, p < 0.05; **, p < 0.01; ***,
p < 0.001.
3. Results
3.1. GSK-J4 treatment inhibited the development of EAE in C57BL/6
mice
Based on previous studies demonstrating the in vitro potential of
GSK-J4 to restrain the inﬂammatory response of macrophages [13],
to affect T-cell differentiation and that Jmjd3-deﬁcient mice wereresistant to the induction of experimental autoimmune encepha-
lomyelitis (EAE) [14], we address the question of whether this drug
exerts a therapeutic effect in vivo in the context of autoimmunity.
For this purpose, we use the mouse model of MS, the EAE.
Accordingly, we immunized C57BL/6 wild-type mice with MOG35-
55 peptide emulsiﬁed in CFA as previously described [34], followed
by daily intraperitoneal injections (i.p.) of GSK-J4 or vehicle for 5
days after EAE induction (Fig. 1A). Then, we compared the sus-
ceptibility of untreated and GSK-J4-treated mice to develop the
disease. The results show that administration of GSK-J4 signiﬁ-
cantly reduced the severity of the disease when compared with
control mice (maximum severity of 2.13 ± 1.13 in GSK-J4-treated
mice versus 4.25 ± 1.04 in control mice, Fig. 1B and C). Addition-
ally, GSK-J4 treatment delayed the onset of the disease compared
with untreated mice (onset of 18.14 ± 2.79 in GSK-J4-treated mice
versus 15.50± 2.27 in control mice, Fig.1 B and C). In addition to the
post-induction treatment of EAE with GSK-J4, we also tested the
therapeutic potential of this drug by administrating it in a post-
onset regime. For this purpose, we injected GSK-J4 or the vehicle
i.p. daily for ﬁve consecutive days starting the day after the onset.
Strikingly, the results show that evenwhen administrated after the
onset, GSK-J4 exerted a therapeutic effect in EAE manifestation
(Fig. S1). These data demonstrate that systemic administration of a
highly selective inhibitor of H3K27m3 demethylases exerts a
therapeutic effect attenuating EAE development and progression.
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phenotypic stability and suppressive function through its action on
DCs
Considering the pivotal role of pro-inﬂammatory Th1 and
Th17 cells, as well as the anti-inﬂammatory effects of Tregs on EAE
development [19e26], we next investigated the role of GSK-J4 on
the polarization of naïve CD4þ T cell to these different subsets
in vitro. For this purpose, naïve CD4þ T-cells (CD4þCD25-Foxp3-)
puriﬁed from C57BL/6 Foxp3-GFP mice were cultured under Th1,
Th17 or Treg polarizing conditions for 4 days in the presence of
splenic DCs plus anti-CD3 in the presence or absence of GSK-J4.
Intracellular expression of IFN-g, IL-17A, and Foxp3-GFP was
assessed by FACS, as indicators of Th1, Th17 and Treg differentia-
tion, respectively. Interestingly, the results showed that GSK-J4
treatment increased the production of Treg cells from 35.4% to
47.8% and 53.7% in the presence of 10 and 25 nM of GSK-J4,
respectively (Fig. 2A). Conversely, GSK-J4 had no effect on the
generation of Th17 or Th1 cells (Fig. 2B and C; Fig. S2).
Since tolerogenic DCs can favor the differentiation of naive
CD4þ T-cells into Tregs, we wondered whether the GSK-J4-
mediated potentiation of Treg differentiation observed in co-
cultures was due to a direct effect on T cells or, alternatively, was
this drug indirectly acting through an effect on DCs. To address this
question, we generated Tregs in the absence of DCs using anti-CD3
and anti-CD28 to stimulate T-cells. As seen in Fig. 3A, GSK-J4 did not
alter the differentiation of Tregs in the absence of DCs, suggesting
that the drugwas acting on DCs rather than directly on naïve Tcells.
To conﬁrm this idea, splenic DCs were preincubatedwith GSK-J4 for
16 h, washed and then tested for their ability to promote TregFig. 2. GSK-J4 favors Treg differentiation without effect on Th1 and Th17 differentiation.
activated with DCs and anti-CD3 under (A) Treg, (B) Th17 or (C) Th1 polarizing conditions in
with PMA/ionomycin in the presence of brefeldin A for 4 h and then IL-17A and IFN-g exp
panels. Numbers represent the frequencies of cells in the corresponding quadrant. In right p
from at least ﬁve independent experiments are shown. Horizontal lines represent average p
ANOVA with post Dunnett's test.differentiation. Pretreatment of DCs with 10 or 25 nM GSK-J4
resulted in an increased Treg differentiation of 9% and 18%,
respectively, when compared with Treg generation in the absence
of the drug (Fig. 3B). Moreover, when DCs were exposed to lipo-
polysaccharide (LPS), a proinﬂammatory glycolipid, Treg differen-
tiation was reduced (Fig. 3B). Nevertheless, when DCs were
exposed to GSK-J4 in the presence of LPS, the drug showed a
stronger effect favoring Treg differentiation (Fig. 3B). Thus, together
these data strongly support the idea that GSK-J4 acts on DCs, but
not directly on CD4þ T-cells, in the potentiation of Treg generation.
It has been suggested that Foxp3þ Treg cells might become
unstable under certain inﬂammatory conditions and might adopt a
phenotype characteristic of effector CD4þ Tcells [36]; therefore, we
tested the effect of GSK-J4 on Treg stability and plasticity. For that
purpose, naïve T cells were polarized toward a Treg phenotype for 4
days in the presence or absence of GSK-J4 and the resulting
CD4þFoxp3þ Treg cells were puriﬁed by cell sorting (Fig. S3). These
cells were further co-cultured with splenic DCs under Th1 or Th17
polarizing conditions for an additional 4 days and analyzed for IFN-
g, IL-17A and Foxp3-GFP expression. As shown in Fig. 4, GSK-J4
reduced the number of Treg converting to Th17 or Th1, while at
the same time it increased the proportion of T cells that retained
Foxp3 expression. Therefore, our data show that Tregs generated
under GSK-J4 treatment are more stable and less susceptible to
convert towards Th1 or Th17 proinﬂammatory phenotypes.
Finally, to determine if GSK-J4 affected the suppressive capacity
of Treg cells, the proliferation of responder effector CD4þ T cells
was assessed following polyclonal stimulation with splenic DCs
plus anti-CD3 in the presence of varying ratios of isolated
CD4þFoxp3þ Treg cells generated in presence or absence of GSK-J4.Naïve CD4þCD25-Foxp3- T cells were isolated from Foxp3-GFP mice by cell-sorting and
the absence or presence of 10 nM or 25 nM GSK-J4 for 4 days. Cells were restimulated
ression were analyzed by ﬂow cytometry. Representative dot-plots are shown in left
anels, the frequencies of (A) Foxp3þ, (B) IL-17Aþ or (C) IFN-gþ CD4þ T cells obtained
ercentage ±SEM. ns, no signiﬁcant; *, p < 0.05; **, p < 0.01 as determined by one-way
Fig. 3. GSK-J4 promotes Treg generation through an effect on DCs. (A) Naive CD4þ T cells isolated from Foxp3-GFP mice by cell-sorting were incubated under Treg polarizing
conditions for 4 days in the absence of DCs and treated with increasing concentrations of GSK-J4. (B) Splenic DCs that were pre-incubated 16 h with 0, 10 or 25 nM GSK-J4 in the
presence or absence of 100 ng/mL LPS and then co-cultured with naive CD4þ T cells obtained from Foxp3-GFP mice under Treg polarizing conditions for 4 days (A and B). After the
incubation period, levels of GFP expression was determined by ﬂow cytometry. Representative dot-plot are shown in left panels. Numbers represent the frequencies of cells in the
corresponding quadrant. In right panels, the frequencies of Foxp3þ CD4þ T cells obtained from at least ﬁve independent experiments are shown. Horizontal lines represent average
percentage ±SEM. ns, no signiﬁcant; *, p < 0.05; ***, p < 0.001; as determined by one-way ANOVA with post Dunnett's test.
C. Do~nas et al. / Journal of Autoimmunity 75 (2016) 105e117110Fig. 5 shows that Treg suppressed proliferation in a dose-dependent
manner and that Treg generated in the presence of GSK-J4 sup-
pressed responder T cells proliferation signiﬁcantly more that un-
treated Treg cells.
Taken together, these results show that GSK-J4 acts upon DCs
promoting the differentiation of Treg cells, improving Treg stability
and suppressive capacities, without affecting the differentiation of
Th1 and Th17 cells.3.3. GSK-J4 impairs DC maturation while inducing tolerogenic
markers in vitro
Dendritic cells are capable of modulating the outcome of the
immune response depending on their maturation state, resulting in
T-cell-mediated immunity accompanied by the production of
proinﬂammatory cytokines or in tolerance mediated by Tregs.
Because our previous results showed that GSK-J4 promotes DC-
driven Treg differentiation, we investigated whether the drug
affected the maturation state of DCs. DCs cultured with medium
alone or LPS were used as controls. As expected, LPS, a stimulator of
DC maturation, increased the percent and surface expression of
CD80, CD86, and MHCII (Fig. S4) on DCs. When analyzing DCs
incubated in the presence of GSK-J4, we found that the drug
signiﬁcantly decreased the population of CD80þ and CD86þ DC
population (Fig. 6A). When tested in combination with LPS, GSK-J4
signiﬁcantly reduced the CD80 and CD86 mean ﬂuorescence in-
tensity (MFI) on DCs (Fig. 6A). However, no differences wereobserved in the expression or MFI of MHCII and CD40 (Fig. 6A).
These data indicate an anti-maturation effect by GSK-J4 on DCs. To
further characterize the changes on DCs upon GSK-J4 treatment, we
analyzed the expression of surface markers involved in the induc-
tion of suppressive response. GSK-J4 signiﬁcantly increased the
CD103þ and TGF-b1þ populations, while decreasing the PDL-1þ
population in DCs or LPS-DCs (Fig. 6B), although no changes were
observed in the MFI of any these markers, further supporting the
tolerogenic effect of GSK-J4. Finally, we monitored cytokine secre-
tion by GSK-J4-treated DCs. As expected, LPS increased IL-6, IFN-g
and TNF production by DCs, whereas 25 nM GSK-J4 showed a
strong inhibitory effect on the secretion of these proinﬂammatory
cytokines (Fig. 6C), showing a similar IFN-g proﬁle of expression to
that of immature DCs (not exposed to LPS) (Fig. 6C).
Collectively, these results indicate that GSK-J4 prevents DC
maturation and leads to a tolerogenic population of DCs, thus
explaining its role in inducing the generation of Tregs.3.4. GSK-J4 modiﬁes the methylated status of histone H3 on the
promoter of IL-6 and TGF-b1 in DCs
The observed induction of a tolerogenic phenotype in DCs by
GSK-J4 treatment raised the question of whether GSK-J4 was
regulating the methylation status of histone H3 in DCs. For this
purpose, we incubated DCs in the presence or absence of GSK-J4
and LPS and then the methylation status of repressive
(H3K27me3) and permissive (H3K4me) markers on histone H3
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Fig. 4. GSK-J4 favors Treg stability by impairing conversion towards Th1 and
Th17 cells. Naive CD4þCD25-Foxp3- T cells were isolated from Foxp3-GFP mice by cell-
sorting and activated under Treg polarizing conditions with or without 10 nM GSK-J4.
Four days later, GFPþ T cells generated were isolated by cell-sorting and re-activated
under Th17 (A) or Th1 (B) polarizing conditions for four days. Afterward, cells were
restimulatedwith PMA and ionomycin for 4 h and then GFP, IL-17A and IFN-g expression
was determined by ﬂowcytometry. Graphs on the left show the percentage of IL-17A (A)
and IFN-g (B) producing cells, while graphs on the right show the percentage of Foxp3-
retaining population. Data from three independent experiments are shown. ns, no sig-
niﬁcant; *, p < 0.05; **, p < 0.01 as determined by two-tailed paired Student's t-test.
C. Do~nas et al. / Journal of Autoimmunity 75 (2016) 105e117 111were analyzed bywestern blot. GSK-J4 increased the global levels of
H3K27me3 in DCs and LPS-DCs, without affecting the global levels
of H3K4me3 (Fig. 7A). We then evaluated the levels of enzymes
involved in the methylation and de-methylation of H3K27 in DCs.
Our results show that neither Ezh2 (methylase) [37] nor JMJD3
(demethylase) were affected by the drug as determined by westernFig. 5. GSK-J4-Tregs present higher suppressive capacity. (A) Treg suppression assays of T
puriﬁed by cell sorting from each group were added to Violet-labeled CD4þCD25- effector T
proliferating T cells is shown in each plot. Data are representative of three independent exper
of anti-CD3, dendritic cells and Tregs generated with or without 10 nM of GSK-J4. Data fro
paired Student's t-test.blot. These results suggest that GSK-J4 inhibits H3K27me3 deme-
thylase activity on DCs.
We then analyzed in DCs the methylated status of histone H3 at
the IL-6 and TGF-b1 promoters, two genes involved in the devel-
opment of Treg, by chromatin immunoprecipitation (ChIP). GSK-J4
treatment led to higher H3K27me3 (repressive) and reduced
H3K4me3 (permissive) levels on the IL-6 promoter in DCs as well as
on LPS-DCs (Fig. 7B). On the other hand, upon GSK-J4 treatment,
H3K27me3 levels were reduced and H3K4me3 levels were
increased on the TGF-b1 promoter in both DCs and LPS-DCs
(Fig. 7C). These data correlate with IL6 secretion and TGF-b1
expression (Fig. 6).
Collectively, these data support the idea of a role of histone
demethylase activity in the differentiation of DCs and conﬁrm that
GSK-J4 treatment induces a tolerogenic phenotype in DCs by
changing the ratio of H3K27me3 and H3K4me3 at speciﬁc gene
promoters.3.5. GSK-J4 pretreated DCs confer protection to EAE after adoptive
transfer
The data presented so far show that DCs are modulated by GSK-
J4 in vitro; however, to establish the role of DCs in GSK-J4-mediated
immunoregulation, we investigated whether GSK-J4-treated DCs
can confer protection after adoptive transfer in the EAE model. For
this purpose, we used pMOG-pulsed bone marrow-derived den-
dritic cells (BMDCs) from C57BL/6 mice, cultured with or without
GSK-J4, washed and adoptively transferred to C57BL/6 mice prior to
EAE induction. Two doses of 1  106 DCs per mouse were used.
After EAE induction, mice adoptively receiving in vitro GSK-J4-
treated DCs had signiﬁcantly lower clinical scores than vehicle-
treated DCs (Fig. 8A). This result indicated that DCs previously
exposed to GSK-J4 are able to mediate protection from autoim-
munity in vivo.
Because of the pivotal role of CNS-inﬁltrating Th1, Th17, and Tregregs generated in the absence (-GSK-J4) or presence of 10 nM GSK-J4 (þGSK-J4). Tregs
cells co-cultured with splenic dendritic cells plus anti-CD3 antibody. The percentage of
iments. (B) Quantitation of the percentage ± SEM of proliferation of Teff in the presence
m three independent experiments are shown. *p < 0.05 as determined by two-tailed
Fig. 6. GSK-J4-treatment induces a tolerogenic phenotype on DCs. CD11cþ splenic DCs from C57BL/6 mice were either unstimulated or stimulated with 100 ng/mL LPS in the presence or absence of 10 nM or 25 nM GSK-J4 for 16 h.
Afterward, the expression of cell surface maturation markers CD80, CD86, MHCII and CD40 (A) and anti-inﬂammatory molecules CD103, TGF-b1 and PDL-1 (B) was analyzed by ﬂow cytometry. In addition, IL-6, IFN-g and TNF secretion
was evaluated by CBA (C). Values are percentages in top panels (A and B), MFI in bottom panels (A and B) and concentration (C). Data represent mean ± SEM from six independent experiments. ns, no signiﬁcant; *, p < 0.05; **, p < 0.01;
***, p < 0.001 as determined by one-way ANOVA followed by the Dunnett's post hoc test.
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C. Do~nas et al. / Journal of Autoimmunity 75 (2016) 105e117 113CD4þ T cells in the outcome of EAE [19e26], we examined the
functional phenotypes of CD4þ T cells inﬁltrating the CNS at the
peak of the disease. At day 20 after disease induction, we isolated
the inﬁltrating mononuclear fraction from the spinal cords and
brains of mice intowhich were transferred either vehicle-treated or
GSK-J4-treated DCs (see Materials and Methods for more details).
Decreased frequencies of two pathogenic CD4þ T-cell populations
that inﬁltrated the CNS were observed, namely IFN-g and IL-17
double producers and GM-CSF producers, while no signiﬁcant
differences were observed in the frequencies of Th1 or Th17 cells
(Fig. 8B). Surprisingly, no differences were detected in the levels of
inﬁltrating Tregs (CD4þFoxp3þ) or in the expression of markers
involved in their suppressive activities (Fig. 8C and D). Moreover, no
differences were found in the inﬁltration of CD8þ or gdT cells
(Fig. S5). Given the fact that no differences were detected in the
levels of inﬁltrating Tregs, we further investigated the in vivo sup-
pressor activity of Tregs generated in the presence of GSK-J4 by
adoptive transference of Tregs in EAE mice. As seen in Fig. 8E, GSK-
J4-generated Tregs reduced the severity of the disease better than
Tregs. These data showed GSK-J4-treated Tregs show a higher
suppressor capacity than Tregs in vivo.
Taken together, these data suggest that GSK-J4-treated DCs are
able to modulate the development of the autoimmune response
in vivo such as in EAE, by reducing the frequency of pathogenic GM-
CSF and IFN-g/IL-17 double producer cells inﬁltrating the CNS and
enhancing the suppressive activity of Tregs.4. Discussion
The demethylase JMJD3 is crucial for the regulation of the
expression of several genes involved in inﬂammatory signaling
pathways [38]. A number of demethylase inhibitors belonging to
the Jumonji C family have been synthesized, but they lackFig. 7. GSK-J4 modiﬁes the levels of H3K27me3 and H3K4me3 associated to promoters of
6 mice were either unstimulated or stimulated with 100 ng/mL LPS in the presence or absen
GSK-J4 were used to detected H3K27me3, H3K4me3, JMJD3 and Ezh2 by western blotting
cipitation (ChIP) assays were performed on DCs and LPS-DCs treated in presence or absence o
immunoglobulin G (IgG), as control. Association of H3K27me3 or H3K4me3 to the promoters
immunoprecipitation. PCR products were normalized to the input DNA and histone H3 levels
p < 0.05; **, p < 0.01; ***, p < 0.001 as determined by two-tailed paired Student's t-test.speciﬁcity [39], with the exception of GSK-J4/J1 [40,41]. According
to Kruidenier and collaborators, GSK-J1/GSK-J4 is the most speciﬁc
inhibitor yet synthetized for the members of the KDM6 subfamily
JMJD3 and UTX [13]. Although a more reﬁned study showed that
GSK-J1/GSK-J4 inhibits to a lesser extent the H3K4me2/me3
demethylase KDM5 subfamily members [40], GSK-J4 remains the
most useful tool for studies involving inhibition of JMJD3 deme-
thylase activity [41]. GSK-J4 was reported to attenuate lipopoly-
saccharide (LPS)-induced pro-inﬂammatory cytokine production in
primary human macrophages in vitro [13] and recently, its effects
on T-cell differentiation have been reported in vitro [14]. However,
the efﬁcacy of GSK-J4 in inﬂammatory or autoimmunity settings
in vivo and its effects on dendritic cells in the context of inﬂam-
mation have not been reported. Consequently, in the present study,
we tested the effect of GSK-J4 in an inﬂammatory setting in vivo,
more speciﬁcally on EAE and its effects on T cells and dendritic cells
in vitro and in an inﬂammatory context. The results showed herein
that GSK-J4 ameliorated the EAE and induced a tolerogenic
phenotype in DCs by changing the ratio of H3K27me3 and
H3K4me3 on speciﬁc promoters. Also, GSK-J4-treated DCs pro-
moted the generation, stability, and suppressive functions of
induced Tregs. Together, these data suggest that GSK-J4 could be
used to treat autoimmune diseases such as MS. Moreover, these
data are the ﬁrst evidence in support of a role for a histone
demethylase in the differentiation of DCs towards a tolerogenic
phenotype. Speciﬁcally, H3K27me3 demethylase activity would act
as a negative regulator of DC differentiation towards a tolerogenic
phenotype and inhibition by GSK-J4 would promote a tolerogenic
phenotype on DCs by changing the ratio of repressive (H3K27me3)
and permissive (H3K4me3) markers at speciﬁc gene promoters.
When GSK-J4 was administered to mice after EAE induction, we
not only observed a signiﬁcant reduction in the clinical signs of the
disease but also a delay in its onset. Because many cell types haveinﬂammatory and anti-inﬂammatory genes in DCs. CD11cþ splenic DCs from C57BL/
ce of 25 nM GSK-J4 for 16 h. Total protein extracts from DCs and LPS-DCs treated with
. Histone H3 and beActin were used as loading control (A). Chromatin Immunopre-
f GSK-J4 using speciﬁc antibodies to H3K27me3, H3K4me3 and rabbit isotype-matched
of IL-6 (B) and TGF-b1 (C) genes was quantiﬁed by qPCR by using speciﬁc primers after
. Values represent mean ± SEM from six independent experiments. ns, no signiﬁcant; *,
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Fig. 8. Ex vivo GSK-J4 treated DCs ameliorates EAE severity and decreases the participation of inﬂammatory subsets of CD4þ T-cells in the CNS. Bone marrow-derived DCs
were pulsed with pMOG, treated with vehicle (white) or with 10 nM GSK-J4 (black) and then transferred (106 DCs/mice; i.v. injections) into wild-type recipient mice at days 14 and 7
prior to EAE induction. (A) Disease severity was evaluated as clinical score from day 0 to day 20 post-induction. Data from ﬁve mice per group is shown, corresponding to a
representative from two independent experiments. (BeD) At the peak of disease severity (day 20), mice were sacriﬁced and mononuclear cells were isolated from CNS followed by
ex vivo re-stimulation with PMA/ionomycin in the presence of brefeldin A, and intracellular cytokine staining analysis was carried out by ﬂow cytometry. Inﬂammatory (B) and anti-
inﬂammatory (C and D) CD4þ T-cell subsets were analyzed. Data represents the percentage of indicated T-cell populations inﬁltrating the CNS. Data from at least three mice per
analysis is shown. Treg generated in absence (white) or presence (black) of 25 nM GSK-J4 and then transferred (0.75*106 Treg/mice; i.v. injections) into wild-type recipient mice at 1
day prior to EAE induction. PBS i.v. injection was used as control. (E) Disease severity was evaluated by clinical score from day 0 to day 35 post-induction. (A, E) Values represent
mean ± SEM. *, p < 0.05; **, p < 0.01; ***, p < 0.001 by Mann-Whitney U test. (BeD) Values represent mean ± SEM. *,p < 0.05; **,p < 0.01, by unpaired Student's t-test.
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ﬂammatory Th1 and Th17 cells and anti-inﬂammatory Treg cells,
we ﬁrst analyzed the effect of the drug on the differentiation of
these CD4þ T-cell subsets from naïve T cells. It has been reported
that JMJD3 is involved in the differentiation of several cell types,
including macrophages and CD4þ T-cell subsets [42e44]. JMJD3
has a role in Th1 differentiation by promoting the activation of
hallmark Th1 genes in a demethylase-dependent manner [45],
while it is induced on Th17 cells after TCR stimulation, binding to
Rorc, Il17a, Il17f, and Il22 genes and promoting their activation also
in a demethylase-dependent manner [14]. Moreover, an alternative
non-demethylase function has already been described for JMJD3
whereby it induces the activation of several hallmark Th1 genes,
including Ifng, by acting as a bridging protein between T-bet and
the SWI/SNF chromatin remodeling complex, which in turn dis-
rupts the histone-DNA interaction [46]. Also, JMJD3 controls Th17
differentiation in a demethylase-independent manner through its
interaction with transcriptional factors to CNS2, a non-coding
sequence that controls the expression of IL-17A [47]. However, in
our setting, GSK-J4 did not alter the differentiation of proin-
ﬂammatory Th1 or Th17 cells in vitro. One explanation is that the
expression of IFN-g and IL-17A could be mainly regulated in a
demethylase-independent manner; thus, the GSK-J4-mediated in-
hibition of the demethylase would not have signiﬁcant effects on
the differentiation of these CD4þ T-cell subsets. Moreover, it has
been shown that GSK-J4 affected CD4þ T-cell differentiation;
nevertheless, the authors used a high concentration of drug and T
cells were stimulated with anti-CD3 and anti-CD28 [14]. Another
possible explanation is that DCs are more sensitive than CD4þ T
cells to the effect of GSK-J4 at a dose of 25 nM. However, these
possibilities are not exclusive and therefore, one or both of themcould explain why Th1 and Th17 differentiation remained un-
changed in vitro when using 10 or 25 nM GSK-J4.
GSK-J4 signiﬁcantly increased the differentiation of anti-
inﬂammatory Treg cells (Fig. 2A), which could explain, at least in
part, the observed beneﬁcial effects on EAE. The mechanisms by
which the promotion of Tregs occurs are not yet fully understood,
but they involve a direct effect of GSK-J4 on thematuration status of
DCs (Fig. 3), which in turn promotes the generation of Tregs. Mature
or proinﬂammatory DCs express higher levels of class II major
histocompatibility complex and costimulatory B7 molecules,
whereas the immature/semi-mature (tolerogenic) phenotype dis-
plays an intermediate expression of costimulatory B7 molecules
[48]. Also, mature DCs secrete inﬂammatory cytokines, such as IL-
12, IFN-g, IL-4, IL-1b, IL-17, or TNF [49e54], whereas tolerogenic
DCs secrete inﬂammatory cytokines at lower levels or not at all [55].
Our data show that GSK-J4 changes the phenotypic proﬁle of DC in
favor of a tolerogenic state (Fig. 6). Interestingly, our results show
that GKS-J4-treated DCs are resistant to maturation in response to
“danger signals” such as LPS (Fig. 6) and that they induce Treg
differentiation in an inﬂammatory context (Fig. 3B), two of themost
important features of tolerogenic DCs [56]. These lines of evidence
show that inhibition of demethylase is important in the develop-
ment of DCs towards a tolerogenic phenotype. Furthermore, GSK-J4
decreased the expression of PDL-1 together with CD80 and CD86 on
DCs. Thematuration status of DCs deﬁnes the proﬁle of activation of
T cells [57]. Functionally, mature DCs stimulate the differentiation
of CD4 T cells towards Th1, Th17, and Th2 cells [58], while tolero-
genic DCs are mediators of T-cell tolerance, by several mechanisms
including the promotion of Treg differentiation from naïve T cells,
which in turn induce a suppressive environment [57]. Thus, the
anti-maturation or tolerogenic effect of demethylase inhibition by
C. Do~nas et al. / Journal of Autoimmunity 75 (2016) 105e117 115GSK-J4 on DCs could explain the increased Treg differentiation
observed under GSK-J4 treatment in vitro. Interestingly, GSK-J4 not
only promoted the generation of Tregs in vitro but also increased
their suppressive capacity (Fig. 3) and stability, making them less
prone to convert to Th1 or Th17 cells (Fig. 4). Moreover, it has been
shown that DCs from the cerebrospinal ﬂuid of patients with MS
have an exacerbated state of maturation [32,33] thus, in vivo GSK-J4
could be causing reversion to this state in EAE, explaining the
beneﬁcial effects of the drug in this inﬂammatory setting.
The role of histone demethylase activity in DC function has not
been studied so far. Although a number of demethylase inhibitors
belonging to the Jumonji C family have been synthesized, they have
proven to have very low speciﬁcity [39]. However, GSK-J4, a JMJD3
and UTX inhibitor, has been shown to be speciﬁc for these enzymes
[13,40,41] and thus remains the most useful tool for studies
involving inhibition of JMJD3 demethylase activity. Our data
showed that the GSK-J4-dependent demethylase activity inhibition
induced global level H3K27me3 enrichment in DCs with no
changes in H3K4me3, as expected. Under inﬂammatory conditions,
JMJD3 demethylase activity decreased H3K27me3 levels of the IL-6
gene promoter and mediated IL-6 expression in endothelial cells
[59]. Our ChIP results showed that LPS increased H3K4me3without
changing H3K27me3, while GSK-J4 treatment increased the
H3K27me3 levels of the IL-6 promoter in DCs and at the same time,
LPS-DCs reduced the H3K4me3 levels in DCs and LPS-DCs, as ex-
pected. These ChIP data, together with the results of IL-6 secretion,
suggest that JMJD3 could directly regulate IL-6 expression in an
H3K27me3 demethylase-dependent manner in DCs, likely in the
same way as in endothelial cells under inﬂammatory conditions,
whereas GSK-J4 treatment induced transcriptional silencing by
Polycomb repressive complexes PCR2 and PCR1 [60] on the IL-6
gene promoter in DCs. On the other hand, our ChIP results
showed that GSK-J4 treatment in DCs reduced H3K27me3 and
increased H3K4me3 levels on the promoter of the TGF-b1 gene
(Fig. 7B). JMJD3 interacts with several transcriptional factors, such
as Smad3, as well as key components of the H3K4 methyl-
transferase complex, such as Ash2L, and even JMJD3 is required to
interact with Smad3-AshL2 and form a stable complex, Smad3-
Ash2L-JMJD3, wherein JMJD3 controls Smad3 target gene expres-
sion via interaction with factor such as Ash2L and binding to pro-
moter regions to active genes [10,44]. Interestingly, TGF-b1 is a
Smad3 target gene and the Smad3 transcriptional factor is neces-
sary for TGF-b1 expression in DCs [61]. Our results for H3K27me3
and H3K4me3 levels on the TGF-b1 promoter by ChIP and TGF-b1
expression by FACS suggest that the inhibition of H3K27me3
demethylase activity by GSK-J4 promotes H3K27me3 demethylase-
independent activity and thus alters methylation status on histone
H3 at lysine 27 and lysine 4 on the TGF-b1 gene promoter in DCs. It
is likely that GSK-J4 treatment could stimulate activity and/or the
formation of a complex such as Smad3-Ash2L-JMJD3, which pro-
motes TGF-b1 expression by increasing H3K4me3 and decreasing
H3K27me3 levels on the TGF-b1 gene promoter in DCs.
Our results also showed that prophylactic adoptive transfer of
DCs treated ex vivo with GSK-J4 ameliorates EAE symptoms
(Fig. 8A). Interestingly, the attenuated severity of EAEmanifestation
was associated with a decreased frequency of two important
pathogenic CD4þ T-cell populations known to inﬁltrate the CNS in
this pathology [29e31], such as IFN-g/IL-17 producers and GM-CSF
producers (Fig. 8B). In this regard, it has been described that irre-
spective of the T-helper phenotype, GM-CSF-producing CD4þ T
cells are the pathogenic CD4þ T cells involved in EAE [29]. The
production of both RORgt and T-bet are necessary for the produc-
tion of GM-CSF and thereby for the manifestation of a pathogenic
Th17 phenotype [29e31,62,63]. It is noteworthy that the co-
expression of T-bet and RORgt could result in the co-productionof IFN-g and IL-17 by these cells, which could correspond to the
IFN-gþIL-17þCD4þ T-cell population observed decreased in the
CNS of EAE mice injected with ex vivo GSK-J4-pretreated DCs
(Fig. 8B). Probably, GSK-J4-treated DCs are able to affect RORgt and
T-bet expression on CD4þ T cells, leading to a partial reduction in
the number of IFN-gþIL-17þCD4þ T cells, as well as in the number
of GM-CSFþCD4þ T cells in the brain of these mice. However, this
effect is not strong enough to affect IFN-gþCD4þ T cells and IL-
17þCD4þ T cells. On the other hand, because in EAE, DCs are in
an inﬂammatory environment in which cytokines and metabolites
needed for Treg differentiation are absent or in low concentrations
[64e67], it is possible that they may be unable to promote differ-
entiation to a Treg phenotype in vivo. This may explain the fact that
no changes were observed in the frequencies of Tregs in vivo upon
adoptive transfer of GSK-J4-treated DCs (Fig. 8C). Moreover, no
changes were observed in tolerogenic molecules in Tregs in vivo,
suggesting that inhibition of Tregs generated by GSK-J4-treated DCs
is independent of these markers and other tolerance molecules
could be evaluated to understand how Tregs generated with GSK-J4
induce tolerance. However, it seems possible that the beneﬁcial
effects GSK-J4 on EAE might involve an increase in the suppressive
function of Tregs trough DCs, as seen in our in vitro data as well as in
our in vivo results on adoptive transference of Treg in EAE mice
(Fig. 8E). Thus, GSK-J4-treated DCs may be capable of maintaining a
tolerogenic phenotype under inﬂammatory conditions, explained
at least in part by an increase in the suppressive function of Tregs
and a partial decrease in the CD4þIFN-gþIL-17þ and
CMGSFþ inﬂammatory phenotypes and the consequent decrease in
clinical score, despite its lack of effect on the Th1 and Th17
phenotypes.
5. Conclusion
The results presented herein indicate that GSK-J4 acts upon DCs,
reducing the clinical course of EAE. We propose that systemic
treatment with GSK-J4 or adoptive transfer of GSK-J4-treated DCs
may be a promising approach for the treatment of autoimmune
diseases, such as EAE. Moreover, our study is the ﬁrst to demon-
strate that H3K27me3 demethylase activity would act as a negative
regulator of DC differentiation towards a tolerogenic phenotype.
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